Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmunodiagnostic Systems Share News (IDH)

Share Price Information for Immunodiagnostic Systems (IDH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 378.00
Bid: 376.00
Ask: 380.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.06%)
Open: 378.00
High: 378.00
Low: 376.00
Yest. Close: 378.00
IDH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Immunodiagnostic Systems recovers 'strongly' in H2

Fri, 16th Apr 2021 07:37

(Sharecast News) - Diagnostic testing kits producer Immunodiagnostic Systems said on Friday that trading had "recovered strongly" in the second half of the year, bouncing back from adverse impacts stemming from the Covid-19 pandemic seen in the first half.
Immunodiagnostic anticipates unaudited revenue from the second-half will be £19.0m, up from £13.7m in the first and representing 39% half-on-half growth. Overall revenues for the twelve months ended 31 March amounted to £32.7m, down from £39.3m in the prior year.

The AIM-listed group stated that the development of its automated business unit strongly correlated with the placement of new instruments, with each new instrument generating recurring incremental revenues, meaning that instrument placements/sales in the division came to 79 in the second half, up from 61 at the same time a year earlier and bringing full-year placements/sales to 100 - the company's strongest rate of placements in eight years.

During the year, Immunodiagnostic stated it had "carefully managed" its cost base, with fixed costs set to be around £3.5m to £4.0m lower than planned as a result of targeted cost actions and changes to working practices aimed at mitigating the impact of the pandemic on underlying earnings.

"The performance of the business during H2 FY21 was extremely positive as all key speciality revenue streams in our Automated Business unit returned to growth and the accelerated rate of placements of new analysers lays the foundation for future growth from recurring assay sales," said the firm.

"We are now very confident that moving forward the revenue growth seen in this business unit pre-pandemic will continue, and most likely accelerate because the Vitamin D products which have historically depressed growth rates are a progressively less significant proportion of the product mix. Thus the underlying growth in the speciality business should increasingly show through."

As of 1030 BST, Immunodiagnostic shares had shot up 13.51% to 210.0p.

More News

AIM WINNERS & LOSERS: Immunodiagnostic surges on PerkinElmer takeover

AIM WINNERS & LOSERS: Immunodiagnostic surges on PerkinElmer takeover

17 May 21 11:15

Immunodiagnostic Systems agrees GBP110 million bid by US's PerkinElmer

Immunodiagnostic Systems agrees GBP110 million bid by US's PerkinElmer

17 May 21 09:21

LONDON BRIEFING: Ryanair hopeful for end of curbs, "gamechanger" jet

LONDON BRIEFING: Ryanair hopeful for end of curbs, "gamechanger" jet

17 May 21 08:13

LONDON MARKET PRE-OPEN: Vistry raises profit guidance on strong demand

LONDON MARKET PRE-OPEN: Vistry raises profit guidance on strong demand

17 May 21 07:52

AIM WINNERS & LOSERS: InfraStrata jumps on joint contract win

AIM WINNERS & LOSERS: InfraStrata jumps on joint contract win

16 Apr 21 11:33

TRADING UPDATES: AFC raises GBP36 million; Angle wins service contract

TRADING UPDATES: AFC raises GBP36 million; Angle wins service contract

16 Apr 21 11:28

Immunodiagnostic Systems recovers 'strongly' in H2

(Sharecast News) - Diagnostic testing kits producer Immunodiagnostic Systems said on Friday that trading had "recovered strongly" in the second half of the year, bouncing back from adverse impacts stemming from the Covid-19 pandemic seen in the first half.

16 Apr 21 07:37

Immunodiagnostic Systems gets emergency FDA approval for Covid-19 test

(Sharecast News) - Clinical laboratory diagnostic technology company Immunodiagnostic Systems (IDS) has reached an agreement with its partner Technogenetics (TGS), it announced on Monday, under which TGS would supply it with a fully-automated SARS-CoV-2 IgG test, to run on its 'IDS-iSYS' analyser, for sales in the United States.

29 Mar 21 12:24

Immunodiagnostic gets US emergency green light for Covid-19 virus test

Immunodiagnostic gets US emergency green light for Covid-19 virus test

29 Mar 21 09:17

Immunodiagnostic Systems launces two rapid Covid-19 tests

(Sharecast News) - Clinical laboratory diagnostics company Immunodiagnostic Systems announced on Friday that two SARS-CoV-2 antigen rapid test kits for Covid-19 were now available for sale in the UK, the European Union, and other countries which accept the CE-mark as the basis of regulatory approval.

27 Nov 20 11:59

UK WINNERS & LOSERS SUMMARY: Immunodiagnostic Up On Covid Kit Rollout

UK WINNERS & LOSERS SUMMARY: Immunodiagnostic Up On Covid Kit Rollout

27 Nov 20 10:49

Immunodiagnostic Systems Notes Rollout Of Covid-19 Rapid Test Kits

Immunodiagnostic Systems Notes Rollout Of Covid-19 Rapid Test Kits

27 Nov 20 10:33

IN BRIEF: Immunodiagnostic Systems Interim Loss Widens On Revenue Drop

IN BRIEF: Immunodiagnostic Systems Interim Loss Widens On Revenue Drop

20 Nov 20 19:25

UK EXECUTIVE CHANGE SUMMARY: InnovaDerma Hires Blake Hughes As New CEO

UK EXECUTIVE CHANGE SUMMARY: InnovaDerma Hires Blake Hughes As New CEO

18 Nov 20 15:42

IN BRIEF: Immunodiagnostic Systems Interim Revenue Falls By 21%

IN BRIEF: Immunodiagnostic Systems Interim Revenue Falls By 21%

23 Oct 20 17:37

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.